Effect of Oculomotor Therapy in Individuals With Convergence Insufficiency

NCT07036263 | Not Yet Recruiting DMC

• 1 other identifier: CI-2025
• Study Type: interventional
• Target: 70
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to investigate the effect of oculomotor therapy in individuals with ocular convergence insufficiency.

Conditions

Convergence Insufficiency

Keywords

Convergence insufficiency; Postural control; Clinical trial

Outcome Measures

Primary Outcomes (1)

• General mobility

  General mobility will be assessed using the Timed 'Up-and-Go' test with time measured in seconds as the unit of measurement.

  3 months

Secondary Outcomes (2)

• Single-Leg Stance Test

  3 months

• Postural Control Assessment

  3 months

Study Arms (2)

Experimental Group (EG)

EXPERIMENTAL

This group will receive treatment with oculomotor therapy

Other: Oculomotor therapy

Control group (CG)

OTHER

This group will not receive any type of treatment

Other: No Treatment Added

Interventions

Oculomotor therapy OTHER

Oculomotor therapy will follow and adapt the protocol for treating convergence insufficiency (CI). Procedures will be organized progressively, from easiest to most difficult. Gross convergence techniques: (1) Brock String: A 1.5-2 m cord with colored beads; the patient focuses on each bead to train binocular fusion, observing the "X" shape of the cord. (2) Barillé Chart: A card with paired images for each eye; the patient merges the images into one using convergence and sensory fusion. Accommodative techniques: (1) Eccentric Circles: Printed circles with eccentric marks; viewed through filters to train motor and sensory fusion by aligning them into a single 3D image. (2) Opaque Lifesaver Cards: Cards with figures on an opaque background, used with red-green filters to stimulate convergence and fixation by reducing peripheral stimuli and enhancing visual attention.

Experimental Group (EG)

No Treatment Added OTHER

Participants in the control group will not receive any type of treatment for a period of five weeks. After this period, they will be re-evaluated

Control group (CG)

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Individuals diagnosed with convergence insufficiency (CI);
• Aged between 18 and 60 years;
• Physically active individuals;
• Without cognitive impairments;
• Without vestibular system impairments (e.g., dizziness).

You may not qualify if:

• Diagnosis of neurodegenerative diseases (e.g., Parkinson's, ALS);
• Presence of dementia;
• History of stroke;
• Presence of vestibular disorders;
• Systemic neuromuscular diseases;
• Disabling musculoskeletal pain;
• Diagnosis of diabetic polyneuropathy;
• Use of joint prostheses;
• Ongoing physical therapy treatment;
• Lack of physical ability to perform the prescribed physical activities.

Sponsors & Collaborators

• University of Nove de Julho: lead

MeSH Terms

Conditions

Ocular Motility Disorders

Condition Hierarchy (Ancestors)

Central Nervous System Diseases; Nervous System Diseases; Cranial Nerve Diseases; Eye Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Assignment randomised clinical trial

Study Record Dates

• First Submitted: June 12, 2025
• First Posted: June 25, 2025
• Study Start: August 1, 2025
• Primary Completion: November 30, 2025
• Study Completion: December 30, 2025
• Last Updated: June 25, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share